XELOX dominant over FOLFOX4 for colorectal cancer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.585, 2009-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FOLFOX4: clear benefit in colorectal cancer

Inpharma, Vol. 1, Iss. 1347, 2002-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Removing oxaliplatin from FOLFOX feasible in colorectal cancer

Inpharma, Vol. 1, Iss. 1528, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

FOLFOX-4 most effective, expensive in colon cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 594, 2010-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

By Madajewicz Stefan

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 772-778

Springer Publishing Company

Access to resources Recommend Favorite

FOLFOX4 feasible first-line therapy for advanced gastric cancer

Inpharma, Vol. 1, Iss. 1498, 2005-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite